ingest cdrApp 2018-03-15T15:00:01.708Z d591f2cd-3da7-4b31-9dd8-ee27dcb6a3ee modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-03-15T15:00:54.860Z Setting exclusive relation addDatastream MD_TECHNICAL fedoraAdmin 2018-03-15T15:01:05.971Z Adding technical metadata derived by FITS addDatastream MD_FULL_TEXT fedoraAdmin 2018-03-15T15:01:28.869Z Adding full text metadata extracted by Apache Tika modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-03-15T15:01:50.882Z Setting exclusive relation modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-05-18T14:57:57.335Z Setting invalid vocabulary terms modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-05-18T14:58:08.698Z modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-05-30T18:27:04.344Z Setting invalid vocabulary terms modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-05-30T18:27:15.473Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-07-11T10:57:04.970Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-07-18T06:56:03.897Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-08-17T12:51:06.154Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-08-21T15:44:49.893Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-09-27T15:50:16.967Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-10-12T07:01:22.814Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-10-17T12:18:19.497Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2019-03-21T16:53:07.720Z Erin Wilson Author Pharmaceutical Sciences DEVELOPING PRINT DRY POWDERS FOR PULMONARY PROTEIN DELIVERY Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. Winter 2017 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor J. Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Pharmaceutical Sciences DEVELOPING PRINT DRY POWDERS FOR PULMONARY PROTEIN DELIVERY Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor J. Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor J. Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor J. Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor J. Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation Pharmaceutical Sciences Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation Pharmaceutical Sciences Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery; Formulation; Inhalation; Protein; Pulmonary; Respiratory eng Doctor of Philosophy Dissertation Pharmaceutical Sciences Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Pharmaceutical Sciences Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Developing Print Dry Powders for Pulmonary Protein Delivery Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery, Formulation, Inhalation, Protein, Pulmonary, Respiratory eng Doctor of Philosophy Dissertation Pharmaceutical Sciences Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Erin Wilson Creator Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy Pulmonary delivery is an attractive route of administration that can be used for the local delivery of therapeutics for respiratory conditions or to non-invasively deliver sufficiently low molecular weight therapeutics to systemic circulation. There is a particular interest in protein delivery, however, many respirable formulations are inefficient at delivering therapeutics to the desired region of the lungs, which precludes the development of costly biologics for inhalation. Particle engineering, a strategy that aims to rationally and precisely control particle size, shape, density, and composition, has been utilized to design high-performance dry powder aerosols that deposit efficiently and precisely in the desired area of the lungs. However, current fabrication methods offer limited control of particle geometry and impose unfavorable stresses on proteins during manufacturing. The overall goals of this dissertation were to fabricate and characterize protein-based microparticles with Particle Replication In Non-wetting Templates (PRINT) technology and engineer these particles into high-performance protein dry powder aerosols. We hypothesized that the precise control of particle geometry afforded by PRINT along with the low physical stress imparted by the process would allow for the stable incorporation of proteins into precisely engineered particles, resulting in high-performance protein dry powder aerosols. A generalizable formulation strategy to micromold a variety of proteins into precisely engineered PRINT particles was developed, and the incorporated proteins were found to retain their native structure and function. Following lyophilization into dry powders, these formulations were found to fluidize, aerosolize, and deposit with high efficiency and precision. We then expanded the formulation strategy to fabricate multiple PRINT particle shapes, which were used to explore the impact of particle shape on dry powder performance in an effort to inform and improve particle engineering strategies. Informed by the formulation development and particle shape studies, dry powder formulations of two therapeutic proteins were developed and the delivery of one formulation was demonstrated in vivo. Overall, we have demonstrated the utility of PRINT as a platform to manufacture high-performance protein dry powders and we have furthered understanding of the impact of particle shape on aerosol performance, both of which contribute to the advancement of particle engineering strategies for inhalable formulations. 2017-12 2017 Pharmaceutical sciences Delivery; Formulation; Inhalation; Protein; Pulmonary; Respiratory eng Doctor of Philosophy Dissertation Joseph M. DeSimone Thesis advisor Philip Smith Thesis advisor David Henke Thesis advisor James Christopher Luft Thesis advisor Michael Jay Thesis advisor Michael Miley Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Wilson_unc_0153D_17370.pdf uuid:538ea769-21ee-4828-a006-4d48bc4a3571 proquest 2017-10-06T15:49:44Z 2019-12-31T00:00:00 application/pdf 22761858